Результаты поиска - Jesper Jørgensen

Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test по Jesper Jørgensen, Panos Kefalas

Connect to this object online.

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate по Jesper Jørgensen, Panos Kefalas

Connect to this object online.

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries по Jesper Jørgensen, Eve Hanna, Panos Kefalas

Connect to this object online.

Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching по Jesper Jørgensen, Laura Mungapen, Panos Kefalas

Connect to this object online.

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson'... по Jesper Jørgensen, Spiros Servos, Panos Kefalas

Connect to this object online.

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy по Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy

Connect to this object online.